Literature DB >> 19584197

Dopamine agonist therapy in prolactinomas: when can treatment be discontinued?

Anne Klibanski.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19584197     DOI： 10.1210/jc.2009-0999

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN： 0021-972X            Impact factor:   5.958


× No keyword cloud information.
  2 in total

1.  Pediatric prolactinoma: initial presentation, treatment, and long-term prognosis.

Authors:  Anika Hoffmann; Sarah Adelmann; Kristin Lohle; Alexander Claviez; Hermann L Müller
Journal:  Eur J Pediatr       Date:  2017-11-22       Impact factor: 3.183

2.  Use of micro-positron emission tomography with (18)F-fallypride to measure the levels of dopamine receptor-D2 and (18)F-FDG as molecular imaging tracer in the pituitary glands and prolactinomas of Fischer-344 rats.

Authors:  Ping Li; Songbai Gui; Lei Cao; Hua Gao; Jiwei Bai; Chuzhong Li; Yazhuo Zhang
Journal:  Onco Targets Ther       Date:  2016-04-06       Impact factor: 4.147
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.